Impel NeuroPharma: Funding, Investors & Team (Oct 2026)
Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Impel NeuroPharma has raised $145M across 3 funding rounds on record, the most recent a Post-IPO Debt of $50.0M announced in Mar 2022.
That round is above the $5.0M median round size for Administrative Services companies tracked on FundedIQ over the last two years.
Impel NeuroPharma Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Impel NeuroPharma Funding Rounds
Impel NeuroPharma raised $50.0M in a Debt Financing announced in Jul 2021.
2 months later, a Post-IPO Equity of $45.0M was announced in Sep 2021.
6 months later, a Post-IPO Debt of $50.0M was announced in Mar 2022.
Impel NeuroPharma Founders and Leadership Team
Contact details for the Impel NeuroPharma team: 2 of 2 have an email address on file.
Start 14-day free trial →Impel NeuroPharma Funding Compared to Other Administrative Services Startups
Impel NeuroPharma's latest round of $50.0M is above the median round in Administrative Services. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Impel NeuroPharma in Administrative Services and Seattle
Companies Similar to Impel NeuroPharma
UpSmith is greatly improving people's lives by providing them with opportunities to receive practical skills…
Parakeet Health is an AI patient engagement platform that helps healthcare organizations improve the patient…
Miter is a platform designed for contractors that focuses on human capital management, field operations, and…
Ema is creating advanced AI solutions that aim to enhance creativity and productivity for all employees in…
Spott is a comprehensive AI-powered application tracking system and customer relationship management tool…
Ottonomy IO is a technology startup that creates autonomous robot fleets for contactless deliveries,…
BrightPlan's mission is to make financial wellness attainable for everyone. BrightPlan is the first financial…
SupplyCaddy produces a range of disposable paper products, which include designs such as packaging, paper,…
Easy Aerial is a leading provider of autonomous drone-based monitoring solutions for commercial, government,…
COR is the next-generation solution for creative and professional teams that intelligently suggests how to…
Rocketlane is building a unified workspace that enables customers to collaborate on onboarding projects.…
Warp is the AI-native Employee Management platform for ambitious companies. Payroll, HR, compliance, benefits…
Impel NeuroPharma Funding FAQs
What does Impel NeuroPharma do?
Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
How much funding has Impel NeuroPharma raised?
Impel NeuroPharma has raised $145M across 3 rounds on record. The most recent is a Post-IPO Debt of $50.0M announced in Mar 2022.
When did Impel NeuroPharma last raise funding?
Impel NeuroPharma's most recent funding round on record is a Post-IPO Debt of $50.0M, announced in Mar 2022.
Who founded Impel NeuroPharma?
FundedIQ lists John Hoekman (Founder) at Impel NeuroPharma.
Who is the CEO of Impel NeuroPharma?
Adrian Adams is listed as CEO at Impel NeuroPharma.
Where is Impel NeuroPharma headquartered?
Impel NeuroPharma is based in Seattle, Washington, United States.
How many employees does Impel NeuroPharma have?
Impel NeuroPharma is in the 101-250 employee band.
How does Impel NeuroPharma's funding compare to other Administrative Services startups?
Impel NeuroPharma's latest round of $50.0M is above the $5.0M median round size for Administrative Services companies on FundedIQ across 1,897 tracked companies over the last two years.
About FundedIQ's Impel NeuroPharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Impel NeuroPharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.